Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.41 |
| ▸ | HINT1 | P49773 | 4/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154875 | 0.94 | TAS1R3 (0.52) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL23169669 | 0.91 | TAS1R3 (0.46) | TAS1R3TAS1R1KDM4EALDH1A1IMPDH2 | |
| SCHEMBL22883219 | 0.89 | TAS1R3 (0.62) | TAS1R3TAS1R1KDM4EIMPDH2IMPDH1 | |
| SCHEMBL19491658 | 0.88 | TAS1R3 (0.51) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL20149816 | 0.88 | TAS1R3 (0.51) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL19503072 | 0.88 | ALDH1A1 (0.55) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL18954932 | 0.88 | ALDH1A1 (0.55) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL18954935 | 0.88 | ALDH1A1 (0.55) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL23169670 | 0.87 | TAS1R3 (0.45) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL25107034 | 0.86 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EALDH1A1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922637-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Pharmaceutica NV (BE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Biopharma, Inc. | 2021-04-01 | — | — | US | disclosed |
| US-20210040483-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | Janssen Biopharma, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | TAS1R3 4579/4885TAS1R1 4780/4885KDM4E 2928/4885 |
| US-20210040483-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | TAS1R3 4526/4885TAS1R1 4768/4885KDM4E 2847/4885 |
| US-20210095284-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | TAS1R3 4177/4885TAS1R1 4657/4885KDM4E 3494/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | TAS1R3 4579/4885TAS1R1 4780/4885KDM4E 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.